Table 3.

Effect of mutations on modulation of GluR2 by CX614

Control (τdeact) Control (τdes) CX614 (τdeact) CX614 (τdes) Fold slowing (τdeact) Fold slowing (τdes) % Des + CX614
WT GluR2(flop) 0.87 ± 0.06 1.21 ± 0.05 23.5 ± 1.48 207 ± 28.2 27 171 37 ± 4d
(21) (18) (13) (10)
WT GluR2(flip) 2.52 ± 0.53 4.76 ± 0.29 8.91 ± 1.05 4 48 ± 3
(6) (6) (6)
S497A 1.86 ± 0.38 2.60 ± 0.53 31.3 ± 1.68 191 ± 28.4 17 73 14 ± 2
(5)a (5)a (6)c,# (6)
S497T 1.03 ± 0.14 1.34 ± 0.14 0.87 ± 0.06 1.32 ± 0.13 1 1 89 ± 3
(9) (8) (6)c,* (5)c,*
S729A 0.93 ± 0.08 1.01 ± 0.06 19.5 ± 2.21 105 ± 10.8 21 104 77 ± 5
(10) (8) (6) (7)c,#
S729T 0.75 ± 0.04 0.98 ± 0.02 25.4 ± 0.69 330 ± 62.4 34 337 10 ± 2
(5) (4) (4) (4)
P494A i 0.37 ± 0.02 0.52 ± 0.03 0.49 ± 0.06 0.64 ± 0.05 1 1 88 ± 4
(21)b (28)b (7) (8)
  • Mean ± SEM data for wild-type (WT) and mutant GluR2 receptors. Three functional parameters were measured in the absence and presence of CX614: the time constant of deactivation (τdeact), the time constant of desensitization (τdes), and the ability of CX614 to block desensitization (Des) during a 500 ms pulse of agonist [% des = (1 — ss/pk)(100)]. For example, mutations that impaired modulation by CX614 (i.e., S497T and S729A) desensitized to a greater extent in the presence of the drug.

    i, Flop variant was nonfunctional; therefore, flip variant was used.

  • a Significantly slower than wild-type control kinetics (p ≤ 0.0001).

  • b Significantly faster than wild-type control kinetics (p ≤ 0.0001).

  • c Significantly different from wild-type GluR2o kinetics in the presence of CX614. *p ≤ 0.0001; #p ≤ 0.01.

  • d Control percentage desensitization in the absence of drug is 94 ± 1%.